Reproduction and Fertility is an open-access, peer-reviewed journal
Page URL: https://www.bionews.org.uk/page_94194

Lords report raises concerns over regenerative medicine in the UK

8 July 2013
Appeared in BioNews 712

A House of Lords committee has said the UK is currently underprepared for developments in regenerative medicine and called on the Government to act to ensure the UK maintains its leading role in the field.

The House of Lords Science and Technology Committee report on Regenerative Medicine concluded that a complex regulatory environment in the UK and a lack of coordinated leadership on regenerative medicine meant that the UK's ability to turn research into clinical application is being held back.

'Private investors are reluctant to invest in regenerative medicine because of the high risks of failure to translate scientific discoveries into widely used treatments', it said. 'The Government could help by simplifying and clarifying the regulatory system, enhancing support for clinical trials and backing innovative funding models'.

The Committee, which makes its recommendations to the Government, sought to identify potential barriers to the future development of regenerative medicine, including potential cell, tissue or organ therapies.

Its recommendations include providing further funding, streamlining the regulatory system, and introducing a Government-led strategy to ensure the NHS is ready to provide regenerative medicine treatments, if and when they become available.

It also called on the National Institute for Health and Care Excellence (NICE) to review its resource evaluation process. It considered the model for evaluating innovative treatments to be 'inappropriate' and said NICE must devise a way of giving suitable consideration to the long-term savings offered by 'high up-front cost treatments'.

It also said the UK Government must take action to protect people from rogue therapies both at home and abroad through the provision of information.

Michael Hunt, Chief Executive Officer of ReNeuron, a stem cell company that gave evidence to the Committee, praised the report as a comprehensive analysis of regenerative medicine in the UK. 'The potential barriers to commercialisation identified in the report are real and important and we endorse the recommendations proposed in the report to address them', he said.

SOURCES & REFERENCES
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
14 October 2013 - by Julian Hitchcock 
Since the Coalition came to power, we've grown used to its backing of science and technology. So, when the Government published its response to the House of Lords Science and Technology Committee Inquiry into Regenerative Medicine last week, there was barely a murmur from the sector as recommendation after recommendation was endorsed and translated into action....
29 July 2013 - by Lanay Tierney 
UK biotech company ReNeuron is to relocate to Wales after securing £7.8m in grants and £5m equity investment from the Welsh government...
17 September 2012 - by James Brooks 
The genetics community needs to work far more collaboratively if it is to meet the challenges of the genomic era, warns Professor Sir John Burn, one of the UK's leading genetics experts...
20 August 2012 - by Dr Emily Culme-Seymour 
The UK House of Lords Science and Technology Select Committee has launched an inquiry into cell therapy and regenerative medicine to take place this autumn...
13 August 2012 - by John Brinsley 
The University of Cambridge is to open a new stem cell institute following an £8million investment from two of the UK's largest medical research funders....
25 July 2011 - by Julianna Photopoulos 
Funding from private, non-profit, and public sectors will be needed for the UK to maintain its 'world leading' role in regenerative medicine, according to a recent Government strategy report....
HAVE YOUR SAY
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.